Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Immunotherapy developer for the treatment of cancer Scancell said the European Patent Office has announced an intention to grant the company's application for a European patent for its modified enolase peptides.
The patent would add to the protection of Scancell's pipeline of Moditope vaccines for the treatment of cancer.
Commercial exclusivity would be provided in all major European territories.